重大新闻！港股强势反弹 恒指涨超160点 生物技术板块领涨

港股强势反弹 恒指涨超160点 生物技术板块领涨

香港 – 2024年6月17日 – 受隔夜美股大幅上涨的提振，香港股市今日强势反弹。恒生指数高开0.93%，开盘后一度升至18,000点以上，最终收报17,906.03点，涨幅0.25%。恒生科技指数涨幅更为明显，上涨1.41%，收报3,772.47点。

板块表现

今日各板块普遍上涨，其中生物技术板块表现最为强劲。百济神州（06160）涨超7%，康芝药业（00332）涨超6%，信达生物（01801）涨超5%。其他涨幅较大的板块还包括医药保健、新能源、银行等。

市场分析

东吴证券分析师表示，全球大宗商品价格处在上涨周期，上游能源行业股价还有继续上涨的空间。此外，美国6月议息会议临近，市场预期美联储将再次加息，也对风险偏好的投资者构成了一定支撑。

展望

展望后市，东吴证券认为，港股短期内仍有望维持震荡上行趋势。建议投资者关注大宗商品、新能源、医药保健等板块的机会。

需要注意的是， 以上新闻稿仅供参考，不构成投资建议。投资者在做出投资决策之前，应仔细考虑自身的风险承受能力和财务状况。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.